ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2024-7-1-19-29ojrdrt-341Research ArticleЯДЕРНАЯ МЕДИЦИНАNUCLEAR MEDICINEПрименение гибридных радионуклидных технологий визуализации и радионуклидной терапии у больных с остеогенной саркомойApplication of Hybrid Radionuclide Imaging Technologies and Radionuclide Therapy in Patients with Osteogenic Sarcomahttps://orcid.org/0000-0002-9571-801XРыжковА. Д.RyzhkovA. D.

Рыжков Алексей Дмитриевич — д.м.н., ведущий научный сотрудник, врач-радиолог отделения радионуклидной диагностики №1 отдела радионуклидной диагностики и терапии НИИ клинической и экспериментальной радиологии НМИЦ онкологии им. Н.Н. Блохина Минздрава России

115478 Москва, Каширское шоссе, 24,

125993 Москва, ул. Баррикадная, 2/1, стр. 1

Alexey D. Ryzhkov

24 Kashirskoye Shosse, Moscow, 115478,

2/1, p. 1, Barricadnaya str., Moscow, 125993

adryzhkov60@yandex.ruhttps://orcid.org/0000-0002-8476-7879КрыловА. С.KrylovA. S.

Крылов Александр Сергеевич — к.м.н., заведующий отделением, врач-радиолог отделения радионуклидной диагностики №1 отдела радионуклидной диагностики и терапии НИИ клинической и экспериментальной радиологии

115478 Москва, Каширское шоссе, 24

AuthorID: 723683,

ScopusID: 57192816516

 

Alexandr S. Krylov

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0003-1632-351XПронинА. И.ProninA. I.

Пронин Артём Игоревич — к.м.н., заведующий отделением, врач-радиолог, руководитель отдела радионуклидной диагностики и терапии НИИ клинической и экспериментальной радиологии

115478 Москва, Каширское шоссе, 24

AuthorID: 901077

Artem I. Pronin

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0003-4122-9285ГелиашвилиТ. М.GeliashviliT. M.

Гелиашвили Тамара Мамуковна — к.м.н., заведующая отделением радионуклидной терапии, врач-радиолог отделения радионуклидной терапии отдела радионуклидной диагностики и терапии НИИ клинической и экспериментальной радиологии

115478 Москва, Каширское шоссе, 24

AuthorID: 1051967

Tamara M. Geliashvili

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0002-7954-2560НиколаеваЕ. А.NikolaevaE. A.

Николаева Екатерина Андреевна — аспирант, врач-радиолог отделения радионуклидной диагностики №1 отдела радионуклидной диагностики и терапии НИИ клинической и экспериментальной радиологии

115478 Москва, Каширское шоссе, 24

Ekaterina A. Nikolaeva

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0003-1308-7646ПавловаА. В.PavlovaA. V.

Павлова Анастасия Викторовна — аспирант, врач-радиолог отделения радионуклидной диагностики №1 отдела радионуклидной диагностики и терапии НИИ клинической и экспериментальной радиологии

115478 Москва, Каширское шоссе, 24

Anastasia V. Pavlova

24 Kashirskoye Shosse, Moscow, 115478

Национальный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава России; Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of Oncology; Russian Medical Academy of Continuous Professional EducationRussian FederationНациональный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation202429032024711929Copyright © Рыжков А.Д., Крылов А.С., Пронин А.И., Гелиашвили Т.М., Николаева Е.А., Павлова А.В., 20242024Рыжков А.Д., Крылов А.С., Пронин А.И., Гелиашвили Т.М., Николаева Е.А., Павлова А.В.Ryzhkov A.D., Krylov A.S., Pronin A.I., Geliashvili T.M., Nikolaeva E.A., Pavlova A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/341Цель

Цель: Продемонстрировать возможности различных гибридных методов исследования костной системы в диагностике первичного очага и метастазов остеосаркомы. Познакомить специалистов с перспективой применения радионуклидной терапии в лечении больных с остеосаркомой.

Материал и методы

Материал и методы: Материал составили наиболее демонстративные случаи из клинической практики НМИЦ онкологии им. Н.Н. Блохина Минздрава России.

Результаты

Результаты: Приведённые примеры показали необходимость привлечения всех возможных радионуклидных модальностей для диагностики и, особенно, мониторинга больных с остеосаркомой для более раннего выявления рецидивов и метастазов.

Выводы

Выводы: Более широкое использование современных гибридных методов исследования (ОФЭКТ/КТ и ПЭТ/КТ) позволяет расширить возможности более раннего выявления метастазов остеосаркомы не только в костях, но и в других органах и тканях.

Purpose

Purpose: To demonstrate the capabilities of various hybrid methods for studying the skeletal system in diagnosing the primary focus and metastases of osteosarcoma. To acquaint specialists with the prospects of using radionuclide therapy in the treatment of patients with osteosarcoma.

Material and methods

Material and methods: The material consisted of the most demonstrative cases from the clinical practice of the N.N. Blokhin National Medical Research Center of Oncology.

Results

Results: The given examples showed the need to involve all possible radionuclide modalities for diagnosis and, especially, monitoring of patients with osteosarcoma for earlier detection of relapses and metastases.

Conclusions

Conclusions: The wider use of modern hybrid research methods (SPECT/CT and PET/CT) makes it possible to expand the possibilities for earlier detection of osteosarcoma metastases not only in bones, but also in other organs and tissues.

остеосаркомаметастазыостеосцинтиграфияОФЭКТ/КТПЭТ/КТрадионуклидная диагностикарадионуклидная терапияosteosarcomametastasesosteoscintigraphySPECT/CTPET/CTradionuclide diagnosticsradionuclide therapyReferencesMebarki M, Medjahedi A, Menemani A, et al. Osteosarcoma pulmonary metastasis mimicking abnormal skeletal uptake in bone scan: utility of SPECT/CT. Clinical Nuclear Medicine. 2013;38(10):392-4.Mebarki M, Medjahedi A, Menemani A, et al. Osteosarcoma pulmonary metastasis mimicking abnormal skeletal uptake in bone scan: utility of SPECT/CT. Clinical Nuclear Medicine. 2013;38(10):392-4.Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure Guideline for SPECT/CT Imaging 1.0. J Nucl Med. 2006;47:1227-34.Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure Guideline for SPECT/CT Imaging 1.0. J Nucl Med. 2006;47:1227-34.Behzadi AH, Raza SI, Carrino JA, et al. Applications of PET/ CT and PET/MR Imaging in Primary Bone Malignancies. PET Clin. 2018 Oct; 13(4):623-34. Published online 2018 Aug 17. https://doi.org/10.1016/j.cpet.2018.05.012Behzadi AH, Raza SI, Carrino JA, et al. Applications of PET/ CT and PET/MR Imaging in Primary Bone Malignancies. PET Clin. 2018 Oct; 13(4):623-34. Published online 2018 Aug 17. https://doi.org/10.1016/j.cpet.2018.05.012Hongtao L, Hui Z, Bingshun W, et al. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: A meta-analysis. Surg Oncol. 2012;21:165-70.Hongtao L, Hui Z, Bingshun W, et al. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: A meta-analysis. Surg Oncol. 2012;21:165-70.Bajpai J, Kumar R, Sreenivas V, et al. Prediction of chemotherapy response by PET-CT in osteosarcoma: Correlation with histologic necrosis. J Pediatr Hematol Oncol. 2011;33:271-8.Bajpai J, Kumar R, Sreenivas V, et al. Prediction of chemotherapy response by PET-CT in osteosarcoma: Correlation with histologic necrosis. J Pediatr Hematol Oncol. 2011;33:271-8.Im HJ, Kim TS, Park SY, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39-49.Im HJ, Kim TS, Park SY, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39-49.Cistaro A, Lopci E, Gastaldo L, et al. The role of 18F-FDG PET/ CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. Pediatr Blood Cancer. 2012;59:1206-10.Cistaro A, Lopci E, Gastaldo L, et al. The role of 18F-FDG PET/ CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. Pediatr Blood Cancer. 2012;59:1206-10.Pevarski D, Drane W, Scarborough. The Usefulness of Bone Scintigraphy with SPECT Images for Detection of Pulmonary Metastases from Osteosarcoma. M. AJR 1998;170:319-22. 0361-803X/98/1702-319.Pevarski D, Drane W, Scarborough. The Usefulness of Bone Scintigraphy with SPECT Images for Detection of Pulmonary Metastases from Osteosarcoma. M. AJR 1998;170:319-22. 0361-803X/98/1702-319.Рыжков АД, Иванов СМ, Ширяев СВ и др. ОФЭКТ/КТ в контроле лучевого лечения костных метастазов остеосаркомы. Вопросы онкологии, 2016;62(5):654-9.Ryzhkov AD, Ivanov SM, Shiryaev SV, et al. SPECT/CT in monitoring radiation treatment of bone metastases of osteosarcoma. Questions of Oncology, 2016;62(5):654-9 (In Russ.).Рыжков АД, Ширяев СВ, Мачак ГН, и др. ОФЭКТ/КТ в контроле лечения костных метастазов остеосаркомы методом ультразвуковой термоаблации. Медицинская радиология и радиационная безопасность. 2016;5:54-8.Ryzhkov AD, Shiryaev SV, Machak GN, et al. Nered. SPECT/CT in monitoring the treatment of bone metastases of osteosarcoma using ultrasound thermal ablation. Medical Radiology and Radiation Safety. 2016;5:54-8 (In Russ.).Рыжков АД, Крылов АС, Мачак ГН, и др. Возможности остеосцинтиграфии и дополнительных радионуклидных методик в диагностике и лечении больных с остеогенной саркомой. Онкологический журнал. Лучевая диагностика, лучевая терапия. 2023;6(2):20-33. https://doi.org/10.37174/2587-7593-2023-6-2-20-33. https://doi.org/10.37174/2587-7593-2023-6-2-20-33. (In Russ.).Ryzhkov AD, Krylov AS, Machak GN, et al. Possibilities of osteoscintigraphy and additional radionuclide techniques in the diagnosis and treatment of patients with osteogenic sarcoma. Oncological Journal. Radiation Diagnostics, Radiation Therapy. 2023;6(2):20-33. https://doi.org/10.37174/2587-7593-2023-6-2-20-33. (In Russ.).Рыжков АД, Крылов АС, Мачак ГН, и др. Мониторинг лечения метастазов остеосаркомы с помощью ОФЭКТ/КТ. Медицинская радиология и радиационная безопасность. 2019;64(4):76-88.Ryzhkov AD, Krylov AS, Machak GN, et al Monitoring the treatment of osteosarcoma metastases using SPECT/CT. Medical Radiology and Radiation Safety. 2019;64(4):76-88. (In Russ.).Петриев ВМ, Тищенко ВК, Красикова РН. 18F-ФДГ и другие меченые производные глюкозы для использования в радионуклидной диагностике онкологических заболеваний (обзор). Химико-фармацевтический журнал. 2016;50(4):3-14.Petriev VM, Tishchenko VK, Krasikova RN. 18F-FDG and other labeled glucose derivatives for use in radionuclide diagnostics of oncological diseases (review). Chemical-Pharmaceutical Journal. 2016;50(4):3-14. (In Russ.).Allott L, Aboagye O. Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals. Mol. Pharmaceutics 2020;17(7):2245-59. https://doi.org/10.1021/acs.molpharmaceut.0c00328.Allott L, Aboagye O. Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals. Mol. Pharmaceutics 2020;17(7):2245-59. https://doi.org/10.1021/acs.molpharmaceut.0c00328.Brenner W, Bohuslavizki KH, Eary JF. PET Imaging of Osteosarcoma J Nuclear Med. June 2003;44(6):930-42.Brenner W, Bohuslavizki KH, Eary JF. PET Imaging of Osteosarcoma J Nuclear Med. June 2003;44(6):930-42.Lodge MA, Lucas JD, Marsden PK, et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22-30.Lodge MA, Lucas JD, Marsden PK, et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22-30.Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med. 1991;32:1655-60.Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med. 1991;32:1655-60.Patlak CS, Blasberg RG. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-90.Patlak CS, Blasberg RG. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-90.Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 1982;257:237-74.Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 1982;257:237-74.Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-88.Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-88.Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010 Dec;31(6):496-505. https://doi.org/10.1053/j.sult.2010.10.001.Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010 Dec;31(6):496-505. https://doi.org/10.1053/j.sult.2010.10.001.Liu, F, Zhang, Q, Zhou, D. et al. Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies. BMC Cancer 19, 323 (2019). https://doi.org/10.1186/s12885-019-5488-5.Liu, F, Zhang, Q, Zhou, D. et al. Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies. BMC Cancer 19, 323 (2019). https://doi.org/10.1186/s12885-019-5488-5.Franzius C, Bielack S, Flege S, et al. Prognostic significance of 18F-FDG and 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002;43:1012-7.Franzius C, Bielack S, Flege S, et al. Prognostic significance of 18F-FDG and 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002;43:1012-7.Hurley C, McCarville MB, Shulkin BL, et al. Comparison of 18F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. Pediatr Blood Cancer. 2016 Aug;63(8):1381- 6. https://doi.org/10.1002/pbc.26014.Hurley C, McCarville MB, Shulkin BL, et al. Comparison of 18F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. Pediatr Blood Cancer. 2016 Aug;63(8):1381- 6. https://doi.org/10.1002/pbc.26014.Page RL, Garg PK, Garg S, et al. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. J Nucl Med. 1994;35:1506-13.Page RL, Garg PK, Garg S, et al. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. J Nucl Med. 1994;35:1506-13.Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985-91.Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985-91.Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-36.Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-36.Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-5.Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-5.Sordillo PP, Benua RS, Gelbard AS, et al. Imaging of human tumors and organs with N-13-labeled L-methionine. Am J Physiol Imaging. 1986;1:195-200.Sordillo PP, Benua RS, Gelbard AS, et al. Imaging of human tumors and organs with N-13-labeled L-methionine. Am J Physiol Imaging. 1986;1:195-200.Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA. 2001;98:9300-5.Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA. 2001;98:9300-5.Franzius C, Bielack S, Flege S, et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin. 01 Dec 2001;40(6):215-20.Franzius C, Bielack S, Flege S, et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin. 01 Dec 2001;40(6):215-20.Anderson P, Wiseman G, Dispenzieri A, et. al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002 Jan 1;20(1):189-96. https://doi.org/10.1200/JCO.2002.20.1.189.Anderson P, Wiseman G, Dispenzieri A, et. al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002 Jan 1;20(1):189-96. https://doi.org/10.1200/JCO.2002.20.1.189.Loeb D, et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009. 115(11):2514-22. https://doi.org/10.1002/cncr.24286.Loeb D, et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009. 115(11):2514-22. https://doi.org/10.1002/cncr.24286.Anderson PM, et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res. 2005. 11(19 Pt 1):6895-900.Anderson PM, et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res. 2005. 11(19 Pt 1):6895-900.Loeb DM, et al Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer 2010.116(23):5470-8.Loeb DM, et al Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer 2010.116(23):5470-8.Subbiah V, Anderson P, Rohren E. Alpha emitter radium 223 in high-risk osteosarcoma: first clinical evidence of response and blood-brain barrier penetration. JAMA Oncol. 2015. 1(2):253-5. https://doi.org/10.1001/jamaoncol.2014.289.Subbiah V, Anderson P, Rohren E. Alpha emitter radium 223 in high-risk osteosarcoma: first clinical evidence of response and blood-brain barrier penetration. JAMA Oncol. 2015. 1(2):253-5. https://doi.org/10.1001/jamaoncol.2014.289.Anderson PM, Subbiah Vk, Rohren E. Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223. Advances in Experimental Medicine and Biology Current Advances in Osteosarcoma. Adv Exp Med Biol. 2014;804:291-304. https://doi.org/10.1007/978-3-319-04843-7_16.Anderson PM, Subbiah Vk, Rohren E. Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223. Advances in Experimental Medicine and Biology Current Advances in Osteosarcoma. Adv Exp Med Biol. 2014;804:291-304. https://doi.org/10.1007/978-3-319-04843-7_16.Subbiah V, Anderson P, Kalevi K, et al. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019;25(13):3802-10. https://doi.org/10.1158/1078-0432.CCR-18-3964.Subbiah V, Anderson P, Kalevi K, et al. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019;25(13):3802-10. https://doi.org/10.1158/1078-0432.CCR-18-3964.Baranowska-Kortylewicz J, Sharp J, McGuire T, et al. Alpha-Particle Therapy for Multifocal Osteosarcoma: A Hypothesis. Cancer Biother Radiopharm. 2020 Aug;35(6):418-24. https://doi.org/10.1089/cbr.2019.3112. Epub 2020 Feb 19.Baranowska-Kortylewicz J, Sharp J, McGuire T, et al. AlphaParticle Therapy for Multifocal Osteosarcoma: A Hypothesis. Cancer Biother Radiopharm. 2020 Aug;35(6):418-24. https://doi.org/10.1089/cbr.2019.3112. Epub 2020 Feb 19.Anderson P. Scott J. Parsai Sh., Zahler St. Worley S. Shrikanthan S. Subbiah V. Murphy E. 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. ESMO Open 2020;5(2):291-304. https://doi.org/10.1136/esmoopen-2019-000635.Anderson P. Scott J. Parsai Sh., Zahler St. Worley S. Shrikanthan S. Subbiah V. Murphy E. 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. ESMO Open 2020;5(2):291-304. https://doi.org/10.1136/esmoopen-2019-000635.Morgenstern A, et al. An Overview of Targeted Alpha Therapy with 225 Actinium and 213 Bismuth. Curr Radiopharm. 2018;11:200-8.Morgenstern A, et al. An Overview of Targeted Alpha Therapy with 225 Actinium and 213 Bismuth. Curr Radiopharm. 2018;11:200-8.Reissig F, Zarschler K, Novy Z, et al. Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA — A Proof of Concept Study. Cancers 2021;13(8):1974; https://doi.org/10.3390/cancers13081974.Reissig F, Zarschler K, Novy Z, et al. Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA — A Proof of Concept Study. Cancers 2021;13(8):1974; https://doi.org/10.3390/cancers13081974.Hagemann UB, et al. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 2016;15:2422- 31.Hagemann UB, et al. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 2016;15:2422- 31.Gott M, Steinbach J, Mamat C. The radiochemical and radiopharmaceutical applications of radium. Open Chem. 2016;14:118-29.Gott M, Steinbach J, Mamat C. The radiochemical and radiopharmaceutical applications of radium. Open Chem. 2016;14:118-29.

The authors declare that there are no conflicts of interest present.